A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 461 participants.

Also called NCT01958671

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 461 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01958671
  • EudraCT 2013-002519-90
Other papers using this trial's data
  • Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study Diabetes, obesity & metabolism, 2018-06 DOI, PubMed 29419917, PMC5969239 In the PMC Open Access subset under CC BY-NC-ND.
  • Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone Diabetes, obesity & metabolism, 2017-05 DOI, PubMed 28116776

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01958671. Randomized; double masking; primary purpose treatment. Start 2013-10-09 (actual); primary completion 2016-07-28 (actual). Results posted on 2017-09-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ertugliflozin 5 mg
Intervention (Drug)
Ertugliflozin 10 mg
Intervention (Drug)
Placebo to Ertugliflozin
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo to Metformin
Intervention (Drug)
Glimepiride
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01958671
Content hash
e3ce6c46ce0536959c530a5e7876ec5748eda1ae461f84b15e8c366d280bd408